Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, Munich, Germany ...

Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary ...

qUniversity of Minnesota Center for Resuscitation Medicine and Division of Cardiology, Minneapolis, MN, USA rDivision of Pulmonary and Critical Care Medicine, Department of Medicine, The Johns Hopkins ...

ABSTRACT: This review focuses on the pulmonary protection strategies during the cooperative period in cardiothoracic surgery. By deeply analyzing the psychophysiology mechanism of pulmonary injury ...

The FDA has approved YUTREPIA™ (treprostinil) inhalation powder, developed by Liquidia Corporation, as a treatment option for adults with pulmonary arterial hypertension (PAH) and pulmonary ...

Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved ...

MANCHESTER, England — Use of immunosuppressive drugs within 5 years of the onset of systemic sclerosis (SSc) did not lower patients’ risk for developing pulmonary arterial hypertension (PAH) but was ...

Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including interstitial lung disease and pulmonary hypertension. Systemic lupus erythematosus (SLE) may ...

According to a new study, this activity at the gym could make you healthier, and it has nothing to do with exercise.

ABSTRACT: Background: Pulmonary embolism (PE), particularly in its severe form, presents a critical clinical challenge requiring immediate intervention. Thrombolytic therapy is widely recognized as a ...

Expert Rev Resp Med. 2008;2(5):539-549. Results from the Third National Health and Nutrition Examination Survey also indicated that patients with severe airflow obstruction had circulating neutrophil, ...